Rilmazafone
| Rilmazafone | |
|---|---|
| Salts [] | |
|---|---|
| Rilmazafone hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 475.30 g/mol [1] |
| Predicted LogP | 2.3 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C21H20Cl2N6O3 |
| IUPAC name | 5-[[(2-aminoacetyl)amino]methyl]-1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-N,N-dimethyl-1,2,4-triazole-3-carboxamide |
| SMILES | CN(C)C(=O)C1=NN(C(=N1)CNC(=O)CN)C2=C(C=C(C=C2)Cl)C(=O)C3=CC=CC=C3Cl |
| InChI | InChI=1S/C21H20Cl2N6O3/c1-28(2)21(32)20-26-17(11-25-18(30)10-24)29(27-20)16-8-7-12(22)9-14(16)19(31)13-5-3-4-6-15(13)23/h3-9H,10-11,24H2,1-2H3,(H,25,30) |
| InChIKey | KYHFRCPLIGODFH-UHFFFAOYSA-N |
| CAS number | 99593-25-6 |
| UNII | CU3H37T766 |
| PubChem CID | 5069 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 10.5 h (M-4 metabolite) |
| Metabolism | Aminopeptidase (intestinal); hepatic |
| Excretion | Urine (44–68% within 24 h, primarily as M-4) |
| Routes of administration | Oral (tablets) |
Rilmazafone (also known as Rilmazafona, Rilmazafonum, S 450191, S-450191, Rilmazafonum [Latin], Rilmazafona [Spanish], Ex-a5707, Da-57446 or 5-(((2-Aminoacetyl)amino)methyl)-1-(4-chloro-2-(2-chlorobenzoyl)phenyl)-N,N-dimethyl-1H-1,2,4-triazole-3-carboxamide) is a substance of the aniline class.
Chemistry
Salts []
Rilmazafone is typically found in the form of its hydrochloride salt.
Stereochemistry []
Rilmazafone is achiral.
Druglikeness
Lipinski's rule of five
Rilmazafone matches Lipinski's rule of five.Pharmacology
MeSH Classification
- hypnotics and sedatives (M0010885)
Interactions []
Interaction mechanisms documented in KEGG DRUG (number of interacting drugs):
| CYP3A4 | induction / metabolism / inhibition | 75 |
|---|---|---|
| GABRA1 | shared target | 10 |
| GABRA2 | shared target | 10 |
| GABRA3 | shared target | 10 |
| GABRA4 | shared target | 10 |
| GABRA5 | shared target | 10 |
| GABRA6 | shared target | 10 |
| GABRB1 | shared target | 10 |
| GABRB2 | shared target | 10 |
| GABRB3 | shared target | 10 |
| GABRD | shared target | 10 |
| GABRE | shared target | 10 |
| GABRG1 | shared target | 10 |
| GABRG2 | shared target | 10 |
| GABRG3 | shared target | 10 |
| GABRP | shared target | 10 |
| GABRQ | shared target | 10 |
| CES | metabolism | 1 |
Subjective effects []
Legal status []
- Other: Rilmazafone is a Rx-only (<small>JP</small>).
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 5069, Rilmazafone. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5069
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Rilmazafone. UNII: CU3H37T766. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/CU3H37T766
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 11:18:56 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 11:18:52 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 11:18:52 |
| gsrs | ok | 2026-11-20 11:18:53 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0257231) | 2026-11-20 11:18:52 |
| kegg | ok | 2026-11-20 11:18:54 |
| pubchem | ok | 2026-11-20 11:18:52 |
| missing (no r/tripreports posts mention it) | 2026-11-20 11:18:52 | |
| sider | missing (not in SIDER) | 2026-11-20 11:18:52 |
| structure | ok | 2026-11-20 11:18:52 |
| wikipedia | ok | 2026-11-20 11:18:52 |